Metabolic Disease Mouse Models
Metabolic Disease Mouse Models
** Enquire to ask for pricing.
Add to cart
Product Description
Metabolic syndrome has become a serious global epidemic that has increased in prevalence over the past several decades. By 2016, over 2.2 billion people were overweight, with over 774 million of those being obese. Type 2 diabetes, which is often exacerbated by obesity, was estimated to afflict 463 million people worldwide in 2019. Comorbidities in the cardiovascular system, the liver, the kidney, the bone and the joints, the GI tract and the immune system have shown clearly that metabolic dysfunction is a multi-system and multi-organ disease. Many studies have shown that both genetic and non-genetic factors (such as lifestyle, nutrition choice and social influence) contribute to the onset of metabolic dysfunction. Developing therapies to combat these metabolic diseases is in urgent need, as is the need for animal models to test the efficacy of such therapies.
| Disease | odel | Genetic Background | Genetic Mutation | Induction Method | Availability Status |
|---|---|---|---|---|---|
| Obesity | DIO (B6J) | C57BL/6J | n.a. | HFD | Yes |
| B6-ob | C57BL/6J | Lep PM | n.a. | Yes | |
| B6-Alms1 mutant | C57BL/6J | Alms1 mutation | n.a. | Yes | |
| B6-hMC4R | C57BL/6J | hMC4R knockin | n.a. | 2022 Q3 | |
| B6-hGPR75 | C57BL/6J | hGPR75 knockin | n.a. | 2022 Q3 | |
| T2DM | HFHSD+STZ | C57BL/6J | n.a. | HFHSD+STZ | Yes |
| BKS-db | BKS | Lepr PM | n.a. | Yes | |
| B6-hGLP-1R | C57BL/6J | hGLP-1R knockin | n.a. | 2022 Q3 | |
| B6-hGCGR | C57BL/6J | hGCGR knockin | n.a. | 2022 Q3 | |
| B6-hGIPR | C57BL/6J | hGIPR knockin | n.a. | 2022 Q3 | |
| B6-Alms1 mutant | C57BL/6J | Alms1 mutation | n.a. | Yes | |
| Dyslipidemia | WD Induced (B6J) | C57BL/6J | n.a. | WD | Yes |
| ApoE KO | C57BL/6J | Apoe knockout | n.a. | Yes | |
| LDLR KO | C57BL/6J | Ldlr knockout | n.a. | Yes | |
| B6-hPCSK9 | C57BL/6J | hPCSK9 knockin | n.a. | Yes | |
| B6-hANGPTL2 | C57BL/6J | hANGPTL2 knockin | n.a. | 2022 Q3 | |
| B6-hANGPTL3 | C57BL/6J | hANGPTL3 knockin | n.a. | 2022 Q3 | |
| B6-hANGPTL4 | C57BL/6J | hANGPTL4 knockin | n.a. | 2022 Q3 | |
| B6-hLPA-tg | C57BL/6J | hLPA random transgene | n.a. | 2022 Q4 | |
| B6-hApoC3-tg | C57BL/6J | hAPOC3 randome transgene | n.a. | 2022 Q4 | |
| B6-hApoA1-tg | C57BL/6J | hAPOA1 random transgene | n.a. | 2022 Q4 | |
| B6-hApoB-tg | C57BL/6J | hAPOB random transngene | n.a. | 2022 Q4 | |
| NASH | HFD+CCl4 | C57BL/6J | n.a. | HFD+CCl4 | Yes |
| BKS-db+WD | BKS | Lepr PM | WD | Yes | |
| B6-Alms1 mutant+WD | C57BL/6J | Alms1 mutation | WD | Yes | |
| WD Induced NASH (B6J) | C57BL/6J | n.a. | WD | Yes | |
| B6-hHSD17B13 | C57BL/6J | hHSD17B13 knockin | n.a. | 2022 Q3 | |
| B6-hPNPLA3 | C57BL/6J | hPNPLA3 knockin | n.a. | 2022 Q3 | |
| Diabetic Nephropathy | BKS-db; eNOS-/- | BKS | Lepr and Nos3 double knockout | n.a. | 2022 Q4 |
| Hyperuricemia | Uox-KO | C57BL/6J | Uox knockout | n.a. | 2022 Q4 |
| Hepatic Fibrosis | CCl4 | Any | n.a. | CCl4 | Yes |
| Arthritis | CIA (DBA/1J) | DBA/1J | n.a. | Collagen II | Yes |
| CIA (DBA-hIl17a) | DBA/1J | hIl17a knockin | Collagen II | Yes | |
| Hemophilia | F8 KO | C57BL/6J | F8 knockout | n.a. | Yes |
| Osteoporosis | B6-hRANKL-OPG KO | C57BL/6J | hRANKL knockin and Tnfrsf11b knockout | n.a. | Yes |
| Psoriasis | IMQ Induced (BALB/c) | BALB/c | n.a. | Imiquimod (5%) | Yes |
| IMQ Induced (BALB/c-hIl17a) | BALB/c | hIl17a knockin | Imiquimod (5%) | Yes |
